Latest Headlines

Latest Headlines

AbbVie hands over $595M upfront to partner with Boehringer on PhIII psoriasis drug

AbbVie is handing over $595 million in an upfront payment to partner with Boehringer Ingelheim on its late-stage psoriasis drug, the anti-IL-23 BI 655066.

Zimmer partners with orthobiologics startup to sell its fracture, bone-void products

Zimmer Biomet has made an exclusive global distribution agreement with recently formed upstart CelgenTek Innovations to distribute its fracture fixation system and a bone-void filler. The CelgenTek N-Force Fixation System enables the injection of either Zimmer's N-Force Blue Bone Substitute Material, which is marketed in the U.S., or CelgenTek's iN3 Cement that is sold in the EU.

San Francisco startup Tiatros partners with IBM Watson on predictive analytics for chronic care networks

Tiatros offers a physician-driven app to enable chronic disease patients to coordinate across providers and to access patient networks. Now, in a deal with the ubiquitous IBM Watson Health, it is integrating cognitive computing applications for that data that are based on predictive natural language analytics.

Medpace signs on to help Actinium get its cancer drug into Phase III

CRO Medpace has signed a deal with Actinium Pharmaceuticals to push the drug developer's lead cancer treatment through late-stage development.

J&J; Depuy does a pair of deals, one to treat disc degeneration and another for bundled payments

Johnson & Johnson's orthopedic arm, Depuy Synthes, has detailed a pair of deals aimed at preparing for its future of that segment. One, with Israeli med tech Rainbow Medical, is slated to develop a treatment for degenerative disc disease (DDD) that could delay or even reverse the degenerative process. The news comes shortly after J&J; disclosed a massive medical device business restructuring in January that would slash 3,000 jobs and save the company $1 billion.

Chinese CRO R&G; buys into Medidata's trial tech

R&G; Pharma Studies, a Chinese CRO, is deepening its relationship with clinical trial tech provider Medidata, adopting the company's cloud-based management system.

Infinity taps CRO Pharm-Olam for a Phase II lymphoma study

Houston CRO Pharm-Olam is on board to help Infinity Pharmaceuticals get its in-development lymphoma therapy through a Phase II trial, recruiting 230 patients in hopes of demonstrating an effect on survival.

South Korea's Yuhan finds U.S. partner Sorrento for immune checkpoint antibodies JV

Seoul-based Yuhan will put up $10 million to work with Sorrento Therapeutics to develop oncology-focused immune checkpoint antibodies from the San Diego company in a joint venture.

IBM Watson unveils its first Apple ResearchKit effort with massive, patient-designed sleep study

IBM and the American Sleep Apnea Association (ASAA) have launched the SleepHealth app to conduct a study to help identify connections between sleep habits and health outcomes. This is the first ResearchKit study that has been run by IBM Watson Health--a business unit that's only about a year old that's dedicated to applying IBM's sophisticated computing capabilities, including artificial intelligence and machine learning, to healthcare problems.

Qualcomm, UnitedHealthcare to develop apps to incorporate wearables, medical devices and Dx

Qualcomm Life will help UnitedHealthcare develop connected health services for its employer wellness program. The healthcare insurance giant has enormous reach, contracting with more than one million healthcare providers and about 6,000 hospitals and care facilities in the U.S.